Signal Transduction
Stem Cells
Signaling Pathways
Product Type
All Products
New Products
Small Molecules
Peptides
Controlled Substances
Toxins
Caged Compounds
Fluorescent Probes
Screening Libraries
Ligand Sets
Other Product Types
Research Area
Cancer
Cardiovascular System
Endocrinology
Immunology
Neuroscience
Pain & Inflammation
Respiratory System
TCS JNK 5aCat. No. 2827 |
Price and AvailabilityBy clicking submit you agree to accept a cookie from Tocris Bioscience. For details, please read our privacy and cookie policy. |
|
Chemical Name: N-(3-Cyano-4,5,6,7-tetrahydrobenzo[b]thienyl-2-yl)-1-naphthalenecarboxamide |
Biological Activity
Selective inhibitor of JNK2 and JNK3 (pIC50 values are 6.7, 6.5, <5.0 and <4.8 for JNK3, JNK2, JNK1 and p38α respectively). Displays no significant activity at a range of other protein kinases including EGFR, ErbB2, cdk2, PLK-1 and Src (pIC50 < 5.0).Certificate of Analysis / Safety Data Sheet
References
Angell et al (2007) N-(3-cyano-4,5,6,7-tetrahydro-1-benzothien-2-yl)amides as potent, selective, inhibitors of JNK2 and JNK3. Bioorg.Med.Chem.Letts. 17 1296.
If you know of a relevant citation for this product please let us know.
View Related Products by Target
Keywords: TCS JNK 5a, supplier, Selective, inhibitors, JNK2, JNK3, Mitogen-Activated, Protein, Kinases, MAPK, c-Jun, N-Terminal, SAPKs, Stress-Activated, TCSJNK5a
Quick Order
Find multiple products by catalog number
Cancer Research Guide
Request your free copy
Highlights over 350 products for cancer research. Request a copy or view PDF today.
Kinases Product Listing
Highlights over 350 products for kinase research. Request a copy or view PDF today.
Kinase Inhibitor Toolbox
80 Kinase inhibitors
pre-dissolved in DMSO
Some of the most potent
kinase inhibitors all on one plate
Includes many of the latest kinase inhibitors to become commercially available. Covers a wide range of kinase targets including EGFR, MAPK and CDK.
Immunology Guide
Highlights over 150 products for immunology research. Request a copy or view PDF today.
MAPK Signaling Review
Written by Elma Zaganjor and Melanie H. Cobb, leading experts. Request a copy or view PDF today.
Calcium Imbalance and Neuroprotective Targets
Written by E. Besancon et al
'Calcium Imbalance and Neuro-protective Targets in Cerebral Ischemia & Brain Injury' highlights the key targets involved in stroke, trauma and neurodegeneration.
New Products in this Area
Selectively inhibits PKC-induced NF-κB activation
20% Discount*
Potent, selective LRRK2 inhibitor
Tocris is the first to launch GSK2578215A, licensed from GlaxoSmithKline, for the study of Parkinson's Disease.